Pulmonx Corp: insider trades · United States · SEC (Form 4)

About Pulmonx Corp

Pulmonx Corp. (ticker: LUNG) is a U.S.-based medical technology company listed on the Nasdaq market in the United States. For French, Belgian, and Swiss investors, it is best viewed as a specialized respiratory-care business focused on minimally invasive treatment of severe emphysema, a debilitating form of COPD. The company was founded in 1995 and has built its franchise around interventional pulmonology, combining therapeutic devices, patient-selection tools, and diagnostic/planning software to support physicians across the treatment pathway. ([stockanalysis.com](https://stockanalysis.com/stocks/lung/company/?utm_source=openai)) The commercial core of Pulmonx is the Zephyr Endobronchial Valve, an implantable bronchial valve designed for selected patients with severe emphysema who remain highly symptomatic despite medical management or who are not suitable for surgical options. The company also markets the Chartis Pulmonary Assessment System, which helps clinicians evaluate airflow and identify appropriate target areas, and the LungTraX platform, a cloud-based quantitative CT analysis service that supports patient identification and procedural planning. This makes Pulmonx more than a single-device company: it is a treatment-enablement platform built around patient screening, physician training, and clinical workflow integration. ([investors.pulmonx.com](https://investors.pulmonx.com/investor-faqs?utm_source=openai)) From a competitive standpoint, Pulmonx occupies a niche leadership position in interventional pulmonology. Its public materials describe the company as a global leader in minimally invasive treatments for lung disease, with commercial availability across the United States, Europe, Australia, Asia, Latin America, and other markets. The corporate headquarters is in Redwood City, California, and the group also maintains a presence in Neuchâtel, Switzerland. That geographic footprint matters because Pulmonx operates in a highly regulated, reimbursement-sensitive market where commercial adoption depends on physician education, procedural infrastructure, and local market access. ([craft.co](https://craft.co/pulmonx/locations?utm_source=openai)) Recent developments have centered on operating execution and financial reporting. Pulmonx released full-year 2025 results and first-quarter 2026 results, with management describing the period as one of transition and emphasizing actions to refocus the U.S. sales organization and advance clinical programs. The company has also highlighted ongoing global adoption of Zephyr Valve procedures. For investors, this creates a classic med-tech profile: differentiated technology with meaningful long-term clinical opportunity, but also dependence on procedure growth, reimbursement dynamics, regulatory execution, and commercialization discipline. On the Nasdaq in the United States, Pulmonx remains a specialized healthcare name with a clear niche, an international footprint, and a risk/reward profile tied to adoption of its lung-volume-reduction platform. ([investors.pulmonx.com](https://investors.pulmonx.com/news-releases/news-release-details/pulmonx-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))